Published in Ann Oncol on October 01, 2002
Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit. Am J Pathol (2008) 0.80
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine (1998) 2.70
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer (1999) 1.81
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Blood platelets and serum VEGF in cancer patients. Br J Cancer (1999) 1.66
Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. Br J Cancer (1998) 1.64
Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol (2001) 1.57
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer (1997) 1.54
Factors constraining adherence to referral advice for severely ill children managed by the Integrated Management of Childhood Illness approach in Imbabura Province, Ecuador. Acta Paediatr (2003) 1.45
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer (2004) 1.44
The influence of a pneumoperitoneum on the peritoneal implantation of free intraperitoneal colon cancer cells. Surg Endosc (1996) 1.38
[Detection of cognitive deterioration in elderly patients attending an emergency hospital service]. Rev Clin Esp (1997) 1.37
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol (2003) 1.35
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer (2003) 1.33
Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer (2002) 1.31
Persistent diarrhoea in Zairian AIDS patients: an endoscopic and histological study. Gut (1988) 1.29
Automated breast tumor diagnosis and grading based on wavelet chromatin texture description. Cytometry (1998) 1.26
Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol (2001) 1.24
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol (2012) 1.22
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res (1998) 1.21
Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol (2000) 1.20
Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer (2007) 1.17
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol (1996) 1.16
Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology (2001) 1.13
Prehospital thrombolytic treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Crit Care Med (1988) 1.13
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol (2009) 1.12
Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis (2001) 1.08
Acute myeloid dendritic cell leukaemia with specific cutaneous involvement: a diagnostic challenge. Br J Dermatol (2008) 1.08
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer (1999) 1.07
Coping with toxicities of docetaxel (Taxotere). Ann Oncol (1993) 1.06
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res (1998) 1.05
Computer-assisted differential diagnosis of malignant mesothelioma based on syntactic structure analysis. Cytometry (1999) 1.02
Correlation between severity of sleep apnea and upper airway morphology based on advanced anatomical and functional imaging. J Biomech (2006) 1.02
Vascular disease of the spleen. Semin Ultrasound CT MR (2007) 1.01
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer (2005) 1.00
The presence of a fibrotic focus is an independent predictor of early metastasis in lymph node-negative breast cancer patients. Am J Surg Pathol (2001) 0.98
Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and in non-neoplastic mesothelium of the pleura using the murine monoclonal antibody JSB-1. J Pathol (1992) 0.98
Comparison of low-dose with standard-dose multidetector CT in cervical spine trauma. AJNR Am J Neuroradiol (2007) 0.98
Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg (2010) 0.96
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer (2006) 0.96
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol (2013) 0.96
Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer (2002) 0.93
Schistosoma mansoni infection causing diffuse enteric inflammation and damage of the enteric nervous system in the mouse small intestine. Neurogastroenterol Motil (2000) 0.90
MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol (2009) 0.89
Soft tissue aneurysmal bone cyst. Skeletal Radiol (2004) 0.88
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat (2008) 0.88
Cystic adventitial disease with secondary occlusion of the popliteal artery. JBR-BTR (2007) 0.87
Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol (1992) 0.87
Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. Br J Dermatol (2010) 0.86
Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis (2011) 0.85
Implantation of colon cancer cells on intact and damaged colon mucosa and serosa: an experimental study in the rat. Acta Chir Belg (1994) 0.85
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol (1998) 0.84
Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol (2012) 0.84
Immunoreactivity for the beta chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol (1992) 0.84
Expression profile of telomerase subunits in human pleural mesothelioma. J Pathol (2000) 0.84
Effect of intestinal inflammation on the cell-specific expression of somatostatin receptor subtypes in the murine ileum. Neurogastroenterol Motil (2007) 0.83
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer (2000) 0.83
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anticancer Drugs (2001) 0.83
Experimental study of intraperitoneal suramin on the healing of colonic anastomoses. Br J Surg (1999) 0.83
Fine structural and cytochemical analysis of the processes of cell death of oocytes in atretic follicles in new born and prepubertal rats. Apoptosis (2006) 0.82
Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. Biomed Res Int (2013) 0.82
Intraoperative sentinel node identification with Technetium-99m-labeled nanocolloid in patients with cancer of the uterine cervix: a feasibility study. Int J Gynecol Cancer (2003) 0.81
Soft tissue sarcoma in adults. Curr Opin Oncol (1997) 0.81
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer (1996) 0.80
Aortic Dissection Limited to Abdominal Aorta: an Underrecognized Entity? Acta Chir Belg (2015) 0.80
Management of cystic pancreatic masses. JBR-BTR (2008) 0.79
Vascular endothelial cell growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle. Eur J Cancer (1998) 0.79
Bilateral occipital condylar fracture with associated haematomas. Emerg Radiol (2006) 0.79
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol (1994) 0.79
Tumor lysis syndrome in a patient with metastatic Merkel cell carcinoma. Cancer (1991) 0.78
Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine (1991) 0.78
Mucocele of the appendix: case report and review of literature. JBR-BTR (2015) 0.78
Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer. Angiogenesis (2004) 0.78
Correspondence re: M. L. George et al., Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res., 6: 3147-3152, 2000. Clin Cancer Res (2001) 0.78
Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med (2002) 0.78
Prognostic value of nonangiogenic and angiogenic growth patterns in non-small-cell lung cancer. Br J Cancer (2004) 0.77
Functional respiratory imaging as a tool to assess upper airway patency in children with obstructive sleep apnea. Sleep Med (2013) 0.77
Tumors and tumor-like lesions of the jaw mixed and radiopaque lesions. JBR-BTR (2006) 0.77
Metronidazole therapy for visceral leishmaniasis. Clin Infect Dis (1994) 0.77
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Ann Oncol (1991) 0.77
Cytokeratin profiles and mucin secretion in combined hepatocellular-cholangiocarcinoma. A case report. Pathol Res Pract (1996) 0.76
A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer (2002) 0.76